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In October 2010, a 55-year-old Chinese woman presented with a T3N3M1a (stage IV) adenocarcinoma of left lung. 
She had left apical main tumor with carcinomatosis of both 
lungs, and metastatic lymphadenopathies of left hilar, right 
paratracheal, right supraclavicular, aortopulmonary, and sub-
carinal lymph nodes. She presented with a Karnofsky perfor-
mance score of 80% and an Eastern Cooperative Oncology 
Group performance score of 1, and had never smoked.
Molecular analysis was performed on a formalin-fixed 
and paraffin-embedded tissue derived by bronchoscopic 
transbronchial biopsy. Tumor cells were isolated from paraf-
fin tissue by manual microdissection. Mutations in exons 18, 
19, 20, and 21 of epidermal growth factor receptor (EGFR) 
gene were analyzed by polymerase chain reaction direct 
sequencing. An insertion mutation in exon 19 was identified: 
c.2232insTAAAATTCCCGTCGCTAT (c.2214_2231dup) 
p.K745_E746insIPVAIK (Fig. 1).
Despite uncertain clinical response of this mutation at 
time of diagnosis, the patient preferred tyrosine kinase inhibi-
tor (TKI) treatment over conventional chemotherapy, after 
detailed discussion with the oncologist. Erlotinib 150 mg 
once daily was initiated in December 2010. Patient’s symp-
toms improved after 3 weeks of treatment, and serial chest 
radiographic findings revealed a stable disease according to 
Response Evaluation Criteria in Solid Tumors criteria in a 
treatment period of 18 months (Fig. 2A–C). She did not suf-
fer from any significant erlotinib toxicity except grade 1 rash. 
Clinical and radiological disease progression was revealed 
after 18 months of erlotinib (Fig. 2D). She was switched to 
two courses of gemcitabine–carboplatin, and then a course of 
pemetrexed–carboplatin, but no clinical response was found. 
She finally succumbed at 24 months after initial diagnosis of 
pulmonary adenocarcinoma.
Insertion mutation in exon 19 of EGFR is an uncommon 
event representing about 2% and 1% of all exon 19 mutations 
and all activation mutations in non–small-cell carcinoma 
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FIGURE 1.  An insertion mutation by duplica-
tion of 18 nucleotides at position 2214_2231 
(c.2232insTAAAATTCCCGTCGCTAT/ c.2214_2231dup) 
in exon 19 leads to the insertion of 6 amino acids 
(p.K745_E746insIPVAIK).
FIGURE 2.  Serial chest radiographic findings before and 
after erlotinib. A, Before treatment: Numerous roundish or 
oval 2- to 3-mm nodular opacities were diffusely presented 
in both lungs. B, One month after treatment: Mild shrinkage 
in size of multiple lung nodules was noted. C, Twelve months 
after treatment: No significant interval change of multiple 
lung nodules was observed. D, Eighteen months after treat-
ment: Mild increase in size and extent of multiple lung 
nodules was evident.
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of lung, respectively.1 Patients with pulmonary non–small-
cell carcinoma harboring insertion mutation in exon 19 are 
sensitive to EGFR-TKI.1 In our local series of 2018 cases 
of pulmonary adenocarcinoma in Hong Kong, 860 cases 
(42.6%) harbor EGFR activation mutation and three of these 
(0.35%) have K745_E746insIPVAIK mutation in exon 19. 
Nucleosides 2212 to 2234 of exon 19 are the insertion muta-
tion hotspots, and duplication of 18 nucleotides at position 
2214 to 2231 (K745_E746insIPVAIK) comprises 41.1% of 
all described insertion mutations in exon 19.1,2 We observed 
a stable disease in a patient with stage IV pulmonary adeno-
carcinoma, which harbored K745_E746insIPVAIK mutation 
in exon 19, under an 18-month treatment of EGFR-TKI. 
This case further supports the responsiveness to TKI in pul-
monary adenocarcinoma with uncommon exon 19 insertion 
mutations.
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